NEW YORK (GenomeWeb News) – Invitrogen last week filed a patent infringement suit against GE Healthcare and other unnamed defendants for allegedly infringing six patents, four of which expired earlier this year.
Invitrogen said in its complaint filed in the US District Court for the Eastern District of Texas Tyler Division that GE Healthcare’s CyScript reverse transcriptase enzymes and kits infringe all six of the patents.
The US patents at issue are Nos. 6,610,522; 6,589,768; 6,063,608; 5,668,005; 5,244,797; 5,405,776. All but the last two expired in January.
Invitrogen is seeking an injunction against GE for sales of products that it believes currently are infringing the last two patents. It also is seeking royalties on past sales of products that it believes GE has infringed. Invitrogen alleged in the complaint that GE’s infringement was willful, which means that it would be entitled to triple damages.